High relapse rate seen at week 72 for patients treated with R1626 combination therapy.
Pockros
Paul
P
Nelson
David
D
Godofsky
Eliot
E
Rodriguez-Torres
Maribel
M
Everson
Gregory T
GT
Fried
Michael W
MW
Ghalib
Reem
R
Harrison
Stephen
S
Nyberg
Lisa
L
Shiffman
Mitchell L
ML
Chan
Anna
A
Hill
George
G
D000998:Antiviral Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006526:Hepatitis C / Q000188:drug therapy* / Q000517:prevention & control*; D006801:Humans; D015994:Incidence; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D009705:Nucleosides / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011355:Prodrugs / Q000627:therapeutic use*; D011994:Recombinant Proteins; D012008:Recurrence; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D009705:Nucleosides; D011355:Prodrugs; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a; C530825:balapiravir